Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03588936
Recruitment Status : Terminated (Halted for convenience due to COVID19 challenges.)
First Posted : July 17, 2018
Last Update Posted : July 22, 2020
Sponsor:
Information provided by (Responsible Party):
Nirav Shah, Medical College of Wisconsin

Brief Summary:
This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed disease post-allogeneic transplant.

Condition or disease Intervention/treatment Phase
Acute Leukemia Chronic Leukemia Lymphoma Myelodysplastic Syndromes Drug: Nivolumab (.25 mg/kg) Drug: Tocilizumab Drug: Nivolumab (.5 mg/kg) Phase 1

Detailed Description:

Study disease: Hematologic malignancies including, but not exclusive to,acute/chronic leukemia, lymphoma, and myelodysplastic syndrome that has relapsed after allogeneic transplant.

Study Rationale: Phase 1 Safety/Dose Finding Study: To determine the safety and maximum tolerated dose of Nivolumab in combination with Tocilizumab.

Study Agent Description:

Tocilizumab is a monoclonal antibody and immunosuppressant; specifically, tocilizumab is an IL-6 receptor antagonist.

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor of T cells blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell proliferation and allowing the immune system to attack the tumor.

Number of Subjects: A maximum of 12 participants will be enrolled on this Phase 1 study.

Duration of Follow-up: Participants will be followed for up to one year post-treatment for survival and response.

Study Design: This is a 3 + 3 design. In a "3 + 3 design," three participants are initially enrolled into a given dose cohort. If there is no dose limiting toxicity (DLT) observed in any of these subjects, the trial proceeds to enroll additional subjects into the next higher dose cohort. If one subject develops a DLT at a specific dose, an additional three subjects are enrolled into that same dose cohort. Development of DLTs in more than one of six subjects in a specific dose cohort suggests that the maximum tolerated dose (MTD) has been exceeded, and further dose escalation is not pursued.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Nivolumab in Combination With Tocilizumab for Treatment of Patients With Relapsed Hematological Malignancies Post-allogeneic Transplant
Actual Study Start Date : September 14, 2018
Actual Primary Completion Date : July 15, 2020
Actual Study Completion Date : July 15, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nivolumab (0.25 mg/kg) and Tocilizumab

Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design).

Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab.

Drug: Nivolumab (.25 mg/kg)
Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Other Name: OPDIVO

Drug: Tocilizumab
Participants will receive 2 doses of tocilizumab
Other Name: ACTEMRA

Experimental: Nivolumab (0.5 mg/kg) and Tocilizumab

Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design).

Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab.

Drug: Tocilizumab
Participants will receive 2 doses of tocilizumab
Other Name: ACTEMRA

Drug: Nivolumab (.5 mg/kg)
Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Other Name: OPDIVO




Primary Outcome Measures :
  1. Maximum-tolerated Dose [ Time Frame: Up to 4 weeks after last dose of study treatment (approximately 3 months) ]
    Determine the safety and the maximum tolerated dose among two candidate doses of nivolumab in combination with tocilizumab for treatment of relapsed hematological malignancy post-allogeneic transplant. Maximum-tolerated dose is based on the determination of dose-limiting toxicities.


Secondary Outcome Measures :
  1. Response Rates Based on Imaging [ Time Frame: End of study treatment (approximately 2 months) ]
    The number of subjects with stable disease as evidenced by imaging (Diagnostic positron emission tomography (PET)-CT scans or CT of the neck, chest, abdomen, and pelvis).

  2. Response Rates Based on Pathologic Response [ Time Frame: End of study treatment (approximately 2 months) ]
    The number of subjects with bone marrow response (achievement of complete response; <5% blasts; stable disease; progressive disease).

  3. Overall Survival [ Time Frame: Up to 1 year from beginning of treatment ]
    The number of participants alive.

  4. Progression-Free Survival [ Time Frame: Up to 1 year from beginning of treatment ]
    Determine the number of subjects alive and in remission after treatment.

  5. Duration of response in responding participants [ Time Frame: Up to 1 year from the beginning of treatment ]
    Number of subjects with complete response or stable disease.

  6. Dose-limiting toxicities [ Time Frame: Up to 4 weeks after last dose of study treatment (approximately 3 months) ]
    The number of subjects with dose-limiting toxicities. This will be measured by the number of adverse events as defined by the NCI CTCAE version 4.03 non-hematologic ≥ grade 3-5 signs/symptoms or by the development of steroid refractory grade 2-4 graft-versus-host disease or severe chronic graft-versus-host disease.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Age≥18 years with hematological malignancies who have undergone allogeneic transplant for hematological malignancy and are ≥180 days post-transplant.
  2. Relapsed disease post-allogeneic transplant defined as follows i. Acute or Chronic Leukemia or myelodysplastic or myeloproliferative disorders or natural killer (NK) cell neoplasms: Bone marrow (BM) with ≥5% disease involvement or peripheral blood evidence of overt relapse ii. Lymphoma: BM evidence of relapsed/persistent disease or PET/CT or CT evidence of persistent/progressive lymphadenopathy consistent with active lymphoma. Active disease defined as nodal lesions ≥ 20 mm in the long axis or extranodal lesions≥10 mm in long and short axis or bone marrow involvement that is biopsy proven
  3. Karnofsky performance status ≥70 (See Appendix A for details)
  4. Creatinine Clearance≥60 ml/min
  5. Adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x upper limit of normal (ULN). Serum bilirubin and alkaline phosphatase ≤3x x ULN, or considered not clinically significant (e.g. Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.
  6. Without evidence of active acute or chronic graft versus host disease (GVHD)
  7. Off all immunosuppression and corticosteroids (other than replacement dose steroids defined as equivalent to a maximum of 10 mg Prednisone daily) for ≥28 days from first treatment.
  8. Off all disease targeted treatments for ≥10 days to first treatment day
  9. Able to provide written informed consent
  10. Women of child-bearing potential and men must agree to use adequate contraception for the duration of study participation and for 120 days after the last treatment with nivolumab.
  11. No FDA approved, more appropriate therapies available for disease control as determined by the treating physician

Exclusion Criteria

  1. Positive beta-human chorionic gonadotropin (HCG) in female of child-bearing potential
  2. Cluster of differentiation 3 (CD3) donor chimerism <5% within 4 weeks of starting study treatment
  3. Prior administration of donor lymphocyte infusion post-allogeneic transplant within the last 6 months of study treatment
  4. History of or active autoimmune disease, or other syndrome that requires systemic steroids.
  5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.
  6. Uncontrolled or active infections on treatment
  7. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.
  8. Presence of ≥grade 3 non-hematologic toxicities as per CTCAE version 5 from any previous treatment unless it is felt to be due to underlying disease.
  9. Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution.

    a. Minimum of 4 weeks from last dose of investigational agent

  10. Prior exposure to PD-1 or CTLA4 antibodies in the post-allogeneic transplant setting. Participants who received such agents pre-allogeneic transplant will NOT be excluded.
  11. Prior exposure to daratumumab in the post-allogeneic transplant setting within two months of start date of treatment with this investigational protocol. Participants who received this agent pre-allogeneic transplant will NOT be excluded
  12. Concurrent therapies targeted at disease relapse. However, previous treatments for relapsed disease are allowed.
  13. Concurrent active malignancy (exceptions: treated solid malignancy in >2 years' remission, treated basal or squamous cell carcinomas of the skin)
  14. History of Crohn's disease or ulcerative colitis
  15. History of demyelinating disorder
  16. Prior intolerance or allergy to tocilizumab

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03588936


Locations
Layout table for location information
United States, Wisconsin
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: Nirav Shah, MD Medical College of Wisconsin
Layout table for additonal information
Responsible Party: Nirav Shah, Assistant Professor, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT03588936    
Other Study ID Numbers: PRO32525
First Posted: July 17, 2018    Key Record Dates
Last Update Posted: July 22, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Hematologic Neoplasms
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Neoplasms by Site
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents